The University of Texas System

Golgi Neurosciences S.r.l.

Axxam S.p.a.

Breye Therapeutics Aps

Valentina Cusano

Paolo Pevarello

Russell Thomas

Domenica Torino

Francesco Piscitelli

Ali Munaim Yousif

Philip Jones

William J Ray

Chiara Liberati

Silvia Bovolenta

Mary Hamby

Yaima Luzardo Lightfoot

Rocco Vitalone

Andrew Griffin

Mariangela Sodano

Elda Severi

Oleksii Artamonov

Disclosed herein are novel cycloalka[b]heteroaryl compounds having CX3CR1/fractalkine receptor (CX3CR1) agonistic properties, pharmaceutical compositions comprising these compounds, chemical processes for preparing these compounds and their use in the treatment or prophylaxis of diseases associated with CX3CR1 receptor activity in animals, in particular humans.

Bicyclic CX3CR1 receptor agonists

Disclosed are compounds of formula (I) or a pharmaceutically acceptable salt thereof, pharmaceutical compositions containing them, and to a process for the preparation of the compounds: Ris independently selected from hydrogen atom, amine group, monocyclic or bicyclic aliphatic, aromatic, heteroaliphatic or heteroaromatic ring. Ris independently selected from monocyclic or bicylic aliphatic, heteroaliphatic, aromatic or heteroaromatic ring, C-Calkyl, alkenyl or alkynyl chain. n is 1 or 2; preferably n is 1. m is 0, 1 or 2; preferably m is 0. Rand Rcan be, independently, &#x2014;H, &#x2014;F, C-Calkyl, &#x2014;OH, &#x2014;OC-Calkyl; preferably they are both &#x2014;H. X is O or S. Ris &#x2014;H or &#x2014;CHoptionally substituted by one or more fluorine atoms; preferably Ris hydrogen. The compounds can be used in the treatment of conditions or diseases mediated by P2X7 receptor.

Heterocyclic P2X7 antagonists

Disclosed are compounds of formula (I) or a pharmaceutically acceptable salt thereof: These compounds have FFA4/GPR120 receptor (FFA4) agonistic properties. Also disclosed are pharmaceutical compositions including these compounds, chemical processes for preparing them and their use in the treatment or prophylaxis of diseases associated with FFA4 receptor activity in animals, in particular humans.

Substituted pyrazoles FFA4/GPR120 receptor agonists

Growing community of inventors

Bresso, Italy

Valentina Cusano